share_log

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $15 Price Target

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $15 Price Target

Wedbush 重申ARS Pharmicals表现跑赢大盘,维持15美元的目标股价
Benzinga ·  2023/08/14 08:17

Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $15 price target.

韦德布什分析师Andreas Argyrides重申ARS制药(纳斯达克:SPRY)表现优异,并维持15美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发